Arcus Biosciences, Inc.
$22.74
▲
5.13%
2026-04-21 09:05:00
arcusbio.com
NYQ: RCUS
Explore Arcus Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.85 B
Current Price
$22.74
52W High / Low
$26.4 / $7.06
Stock P/E
—
Book Value
$5.04
Dividend Yield
—
ROCE
-42.51%
ROE
-63.26%
Face Value
—
EPS
$-3.29
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
601
Beta
0.86
Debt / Equity
34.71
Current Ratio
4.36
Quick Ratio
4.36
Forward P/E
-6.4
Price / Sales
11.34
Enterprise Value
$2.04 B
EV / EBITDA
-5.42
EV / Revenue
8.25
Rating
Strong Buy
Target Price
$34.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aptevo Therapeutics Inc. | $5.21 | — | $6.24 M | — | -124.44% | -2.35% | $486 / $3.8 | $17.42 |
| 2. | Aura Biosciences, Inc. | $7.05 | — | $467.66 M | — | -74.67% | -73.52% | $7.48 / $4.34 | $2.15 |
| 3. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 4. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
| 5. | Alaunos Therapeutics, Inc. | $2.84 | — | $6.71 M | — | -233.25% | -1.98% | $6.2 / $1.67 | $1.27 |
| 6. | Inhibikase Therapeutics, Inc. | $1.81 | — | $238.98 M | — | -30.85% | -36.04% | $2.37 / $1.33 | $1.02 |
| 7. | CollPlant Biotechnologies Ltd. | $0.37 | — | $5.15 M | — | -141.54% | -1.18% | $4.98 / $0.27 | $0.47 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 33 M | 26 M | 160 M | 28 M | 26 M | — |
| Operating Profit | -114 M | -142 M | -8 M | -122 M | -103 M | — |
| Net Profit | -106 M | -135 M | 0 M | -112 M | -94 M | — |
| EPS in Rs | -0.85 | -1.08 | 0 | -0.89 | -0.75 | -1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 247 M | 258 M | 117 M | 112 M |
| Operating Profit | -386 M | -310 M | -340 M | -280 M |
| Net Profit | -353 M | -283 M | -307 M | -267 M |
| EPS in Rs | -2.82 | -2.26 | -2.45 | -2.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.14 B | 1.15 B | 1.09 B | 1.34 B |
| Total Liabilities | 508 M | 665 M | 633 M | 688 M |
| Equity | 631 M | 485 M | 462 M | 657 M |
| Current Assets | 1.01 B | 1.02 B | 831 M | 1.07 B |
| Current Liabilities | 231 M | 226 M | 184 M | 193 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -482 M | -170 M | -306 M | 438 M |
| Investing CF | 66 M | -84 M | 194 M | -413 M |
| Financing CF | 488 M | 277 M | 33 M | 33 M |
| Free CF | -484 M | -176 M | -330 M | 432 M |
| Capex | -2 M | -6 M | -24 M | -6 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 120.51% | 4.46% | — | — |
| Earnings Growth % | 7.82% | -14.98% | — | — |
| Profit Margin % | -109.69% | -262.39% | -238.39% | — |
| Operating Margin % | -120.16% | -290.6% | -250% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -103.88% | -248.72% | -230.36% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.